000119310 001__ 119310
000119310 005__ 20240228145431.0
000119310 0247_ $$2doi$$a10.1016/j.canlet.2016.03.043
000119310 0247_ $$2pmid$$apmid:27045478
000119310 0247_ $$2ISSN$$a0304-3835
000119310 0247_ $$2ISSN$$a1872-7980
000119310 0247_ $$2altmetric$$aaltmetric:6432306
000119310 037__ $$aDKFZ-2017-00065
000119310 041__ $$aeng
000119310 082__ $$a570
000119310 1001_ $$aAbba, Mohammed L$$b0
000119310 245__ $$aMicroRNAs as novel targets and tools in cancer therapy.
000119310 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2017
000119310 3367_ $$2DRIVER$$aarticle
000119310 3367_ $$2DataCite$$aOutput Types/Journal article
000119310 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661770736_21383$$xReview Article
000119310 3367_ $$2BibTeX$$aARTICLE
000119310 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119310 3367_ $$00$$2EndNote$$aJournal Article
000119310 520__ $$aMicroRNAs (miRNAs) are currently experiencing a renewed peak of attention not only as diagnostics but also especially as highly promising novel targets or tools for clinical therapy in several different malignant diseases. Moreover, the recent discovery of competing endogenous RNAs (ceRNAs) as novel miRNA-regulators has contributed exciting insights in this regard. Therefore, this review summarizes and discusses the latest findings on (1) how miRNAs have become therapeutic targets of diverse synthetic antagonists, (2) how novel endogenous regulators of miRNAs such as ceRNAs or pseudogenes could emerge as therapeutics scavenging oncogenic miRNAs and (3) how miRNAs themselves are already, and will increasingly be, used as therapeutics. Recent advances on the importance of miRNA-target affinity and the subcellular localization of miRNAs are also discussed. The potential of these developments in different tumor entities and particular hallmarks of cancer such as metastasis, disease progression, interactions with the tumor microenvironment, or cancer stem cells are equally highlighted.
000119310 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000119310 588__ $$aDataset connected to CrossRef, PubMed,
000119310 7001_ $$0P:(DE-He78)e22573706cfe9748cc0e45a526c2bfef$$aPatil, Nitin Shaligram$$b1$$udkfz
000119310 7001_ $$aLeupold, Jörg H$$b2
000119310 7001_ $$aMoniuszko, Marcin$$b3
000119310 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b4$$udkfz
000119310 7001_ $$aNiklinski, Jacek$$b5
000119310 7001_ $$0P:(DE-He78)69067807288b48415ceb4abc43b9ad54$$aAllgayer, Heike$$b6$$eLast author$$udkfz
000119310 773__ $$0PERI:(DE-600)2004212-7$$a10.1016/j.canlet.2016.03.043$$gVol. 387, p. 84 - 94$$n387$$p84 - 94$$tCancer letters$$v28$$x0304-3835$$y2017
000119310 909CO $$ooai:inrepo02.dkfz.de:119310$$pVDB
000119310 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e22573706cfe9748cc0e45a526c2bfef$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119310 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119310 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69067807288b48415ceb4abc43b9ad54$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000119310 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000119310 9141_ $$y2017
000119310 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000119310 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER LETT : 2015
000119310 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119310 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119310 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119310 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119310 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119310 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119310 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119310 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119310 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119310 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119310 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119310 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER LETT : 2015
000119310 9201_ $$0I:(DE-He78)G360-20160331$$kG360$$lKKE Molekulare Onkologie solider Tumoren$$x0
000119310 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x1
000119310 980__ $$ajournal
000119310 980__ $$aVDB
000119310 980__ $$aI:(DE-He78)G360-20160331
000119310 980__ $$aI:(DE-He78)G300-20160331
000119310 980__ $$aUNRESTRICTED